Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A phase 3 trial of Ziftomenib, Venetoclax, Azacitidine, Daunorubicin and Cytarabine in acute myeloid leukaemia, run by Kura Oncology, Inc., now recruiting.
Overview
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML is a phase 3 interventional study registered as NCT07007312 by Kura Oncology, Inc., with 1300 participants planned, started 2025-09-26 and due to reach its primary completion in 2031-11. Interventions recorded: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin and Cytarabine (Ara-C).
Similar pages
not linked directly; found by shared links- TrialA Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Shares Daunorubicin, Cytarabine, Azacitidine, Venetoclax and the tag pipeline.
- TrialGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Shares Cytarabine, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Shares Daunorubicin, Cytarabine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialStudy of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.